Medical Devices DECODED
Previous edition: 15 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
PhotoPharmics brings in first PD patients for phototherapy device trial
PhotoPharmics is aiming to enrol 300 patients with Parkinson’s disease in a pivotal trial evaluating its phototherapy device.
PhotoPharmics has enrolled the first patients with Parkinson’s disease (PD) in a study aimed at demonstrating the efficacy of its phototherapy device in improving symptoms of the disease.
The first 25 patients enrolled are part of a 300-strong target for the US-based company in the trial that will provide further evidence for PD treatment.
The pivotal trial for PhotoPharmics’ device, named Celeste, is designed to improve both motor and non-motor function, as well as overall quality of life for patients with PD. A pivotal trial for a medical device is similar to a Phase III trial for a drug, the final stage of clinical research before marketing applications are submitted to regulatory agencies.
The Celest Light for PD trial (NCT04453033), conducted in collaboration with the University of Rochester Medical Centre, will see participants in the US use the Celeste device for one hour a day. Patients’ quality of life will be assessed via questionnaires at 26 weeks.
Whilst there are many US Food and Drug Administration (FDA)-approved drugs for PD, there is a lack of devices on the market that target symptoms beyond tremors.
PhotoPharmics’ CEO Kent Savage said the last thing many PD patients want is another drug.
“Our goal has been to provide a non-invasive therapy that would significantly improve Parkinson’s symptoms beyond what is currently available,” he added in a statement.
Light therapy, which can be used at home during normal evening activities, involves bathing the face in a special light. According to PhotoPharmics, the light targets photoreceptors in the eyes responsible for circadian rhythm – the day-by-day biological cycles that help many bodily functions. This means PD symptoms such as sleep disturbances, fatigue, psychological health, and cognition can be addressed with light therapy. The device is designed to be used on top of current medication.
The device has already won an FDA breakthrough device designation back in 2020, meaning PhotoPharmics is eligible for a streamlined premarket review phase.
One major advantage to the trial’s at-home and telemedicine-based format is that a broader and more diverse population can be recruited.
The number of Parkinson’s cases will grow to nearly three billion in 2029 in the seven major markets (UK, US, France, Germany, Italy, Spain, and Japan), up from from 2.4 billion cases in 2019, according to analysis by GlobalData.
PhotoPharmics's chief science officer Dan Adams said: “As patients reported in our prior trial, this may be the first treatment that improves a broad set of functional abilities in PD when administered on top of current medication. We recently presented our new trial design to the FDA with a favourable review."
Latest news
FDA issues recall notice for Philips after another respiratory device fails
The FDA has issued the notice for the company’s Trilogy EVO Continuous Ventilators, warning that they are liable to be ‘battery depleted’ despite being connected to power and halting therapy.
Meacor secures $15m for heart valve repair technology development
The technology is poised to provide an effective solution to halt regurgitation.
Saladax receives approval from Health Canada for 5-FU TDM test
The My5-FU test allows for patient-specific dose adjustments, thereby improving efficacy and reducing toxicity.
Innovate UK funds digital health compliance platform
Innovate UK has awarded the London and Amsterdam-based startup £322k to boost digital healthcare compliance in the NHS.
Brixton Biosciences secures $33m to develop osteoarthritis pain platform
The company will use the capital to initiate two new clinical studies into its pain management platform.
Somnee launches new features of smart sleep headband
The app for the smart sleep headband introduces features such as brain mapping, a sleep journal, and sleep readiness scores.
Profound wins FDA clearance for AI support to Tulsa system
iCAD, Inc, a global medical technology leader providing innovative cancer detection and therapy solutions, announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. Food and Drug Administration (FDA). Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance and up to 1% improvement in sensitivity. ProFound AI Version 3.0 also offers up to 40% faster processing on the new PowerLook platform.
15th Annual Outsourcing in Clinical Trials East Coast 2024
The upcoming Outsourcing in Clinical Trials Europe 2024 conference will explore advancements in the clinical trial industry.
In our previous edition
Medical Devices Decoded
FDA warns users not to use Cue Health's at-home Covid-19 tests
14 May 2024
Medical Devices Decoded
Dementia Action Week 2024: the future of Alzheimer's diagnostics
13 May 2024
Medical Devices Decoded
Neuralink's first brain chip implant faces setback
10 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer